Understanding and targeting resistance mechanisms in NSCLC

Key Points The spectrum of known and putative oncogenic drivers with companion targeted therapies continues to increase. As broader mutational testing becomes more clinically available, a greater proportion of patients with non-small-cell lung cancer (NSCLC) will be eligible for targeted therapies....

Full description

Saved in:

Bibliographic Details
Published in:	Nature reviews. Cancer Vol. 17; no. 11; pp. 637 - 658
Main Authors:	Rotow, Julia, Bivona, Trever G.
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01.11.2017 Nature Publishing Group
Subjects:	631/67/1059/2326 631/67/1059/602 631/67/1612/1350 AKT protein Animals Antineoplastic Agents - pharmacology Biomedicine Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Drug Resistance, Neoplasm - drug effects Epidermal growth factor Epidermal growth factor receptors Genetic aspects Humans Kinases Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lymphoma Microbial drug resistance Mutation Non-small cell lung cancer Non-small cell lung carcinoma Protein-tyrosine kinase receptors Raf protein review-article Risk factors Signal transduction Threonine Tumor microenvironment Tumors
ISSN:	1474-175X, 1474-1768, 1474-1768
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!